A Phase 1, Single-Center, Randomized, Open-Label, Two-Way Crossover, Formulation and Food Effect Study in Healthy Volunteers, to Assess the Pharmacokinetics of AZD 2066 After Single Doses of a New Oral Solid Formulation and an Oral Solution
Latest Information Update: 16 Dec 2010
At a glance
- Drugs AZD 2066 (Primary)
- Indications Gastro-oesophageal reflux; Neuropathic pain
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 25 Jun 2008 New trial record.